Drug Delivery and Disposition, Department of Pharmaceutical and Pharmacological Sciences , KU Leuven , Campus Gasthuisberg O&N2, Herestraat 49 b921 , 3000 Leuven , Belgium.
Department of Pharmaceutics , Hanoi University of Pharmacy , 13-15 Le Thanh Tong , Hoan Kiem , Ha Noi , Vietnam.
Mol Pharm. 2018 Mar 5;15(3):1037-1051. doi: 10.1021/acs.molpharmaceut.7b00930. Epub 2018 Jan 29.
The crystallization of metastable crystal polymorphs in polymer matrices has been extensively reported in literature as a possible approach to enhance the solubility of poorly water-soluble drug compounds, yet no clarification of the mechanism of the polymorph formation has been proposed. The current work aims to elucidate the polymorphism behavior of the model compound indomethacin as well as the mechanism of polymorph selection of drugs in semicrystalline systems. Indomethacin crystallized as either the α- or τ-form, a new metastable form, or a mixture of the two polymorphs in dispersions containing different drug loadings in polyethylene glycol, poloxamer, or Gelucire as the result of the variation in the mobility of drug molecules. As a general rule, low molecular mobility of the amorphous drug favors the crystallization into thermodynamically stable forms whereas metastable crystalline polymorphs are preferred when the molecular mobility of the drug is sufficiently high. This rule provides insight into the polymorph selection of numerous active pharmaceutical ingredients in semicrystalline dispersions and can be used as a guide for polymorphic screening from melt crystallization by tuning the mobility of drug molecules. In addition, the drug crystallized faster while the polymer crystallized slower as the drug-loading increased with the maxima of drug crystallization rate in 70% indomethacin dispersion. Increasing the drug content in solid dispersions reduced the τ to α polymorphic transition rate, except for when the more stable form was initially dominant. The segregation of τ and α polymorphs as well as the polymorphic transformation during storage led to the inherent inhomogeneity of the semicrystalline dispersions. This study highlights and expands our understanding about the complex crystallization behavior of semicrystalline systems and is crucial for preparation of solid dispersions with reproducible and consistent physicochemical properties and pharmaceutical performance.
聚合物基质中亚稳晶体多晶型物的结晶已在文献中广泛报道,这是提高水溶性差的药物化合物溶解度的一种可能方法,但尚未提出多晶型形成的机制。本工作旨在阐明模型化合物吲哚美辛的多晶型行为以及半晶系统中药物多晶型选择的机制。吲哚美辛在含有不同药物载药量的聚乙二醇、泊洛沙姆或 Gelucire 分散体中结晶为α-或τ-形式(一种新的亚稳形式)或两种多晶型的混合物,这是由于药物分子的迁移率不同所致。一般来说,无定形药物的低分子迁移率有利于结晶成热力学稳定形式,而当药物分子的迁移率足够高时,亚稳晶多晶型物则更受欢迎。该规则为半晶分散体中许多活性药物成分的多晶型选择提供了深入的了解,并可通过调节药物分子的迁移率,作为从熔融结晶进行多晶型筛选的指南。此外,随着药物负载的增加,药物结晶速度更快,而聚合物结晶速度更慢,在 70%吲哚美辛分散体中达到药物结晶速度的最大值。增加固体分散体中的药物含量会降低τ到α多晶型转变速率,但当更稳定的形式最初占主导地位时除外。τ和α多晶型物的分离以及储存过程中的多晶型转变导致半晶分散体固有的不均匀性。这项研究强调并扩展了我们对半晶系统复杂结晶行为的理解,对于制备具有可重复和一致的物理化学性质和药物性能的固体分散体至关重要。